Skip to main content
NCBI home page
Annals of Surgery logoLink to Annals of Surgery
. 1979 Sep;190(3):342–349. doi: 10.1097/00000658-197909000-00009

The fibrinolytic system. A key to tumor metastasis?

J M Malone, S L Wangensteen, W S Moore, K Keown
PMCID: PMC1344666  PMID: 485608

Abstract

Neither histologic nor clinical staging reliably correlates with patient survival or the time course of tumor metastatic spread. There is no general biologic tumor marker which is able to distinguish those patients with microscopic residual cancer who may benefit from adjuvant anticancer treatment from those patients cured by their primary treatment who do not require additional anticancer therapy. Our data suggest that tumor activation and inhibition of fibrinolysis are related to the likelihood of tumor spread. Calculation of mean activation/inhibition ratios (A/I ratios) in groups of tumors with and without metastatic spread demonstrated a statistically significant difference between their respective A/I ratios (p less than 0.001). In addition, the mean activation/inhibition ratios for secondary or "metastatic" lesions were significantly different from the mean activation/inhibition ratios of the original tumors from which they metastasized (p less than 0.001). Therefore, tumor activation/inhibition ratios would appear to have clinical reliability as biologic markers for the presence or absence of tumor metastases. These data may have important therapeutic implications that would permit the use of activation/inhibition ratios as a biologic marker for the presence or absence of tumor spread at the time of primary surgical excision of the tumor. These observations warrant further investigation into the mechanisms of tumor interaction with the fibrinolytic system.

Full text

PDF
342

Images in this article

343Fig. 1.
on p.343
343Fig. 2.
on p.343

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. AGOSTINO D., CLIFFTON E. E. Anticoagulants and the development of pulmonary metastases. Anticoagulant effect on the Walker 256 carcinosarcoma in rats. Arch Surg. 1962 Apr;84:449–453. doi: 10.1001/archsurg.1962.01300220073012. [DOI] [PubMed] [Google Scholar]
  2. CLIFFTON E. E., GROSSI C. E. Effect of human plasmin on the toxic effects and growth of blood borne metastatis of the Brown-Pearce carcinoma and the V2 carcinoma of rabbit. Cancer. 1956 Nov-Dec;9(6):1147–1152. doi: 10.1002/1097-0142(195611/12)9:6<1147::aid-cncr2820090613>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  3. CLIFFTON E. E., GROSSI C. E. Fibrinolytic activity of human tumors as measured by the fibrin-plate method. Cancer. 1955 Nov-Dec;8(6):1146–1154. doi: 10.1002/1097-0142(1955)8:6<1146::aid-cncr2820080610>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  4. Christman J. K., Silagi S., Newcomb E. W., Silverstein S. C., Acs G. Correlated suppression by 5-bromodeoxyuridine of tumorigenicity and plasminogen activator in mouse melanoma cells. Proc Natl Acad Sci U S A. 1975 Jan;72(1):47–50. doi: 10.1073/pnas.72.1.47. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Franklin J. D., Gervin A. S., Bowers D. G., Jr, Lynch J. B. Fibrinolytic activator activity in human neoplasms. Plast Reconstr Surg. 1978 Feb;61(2):241–249. doi: 10.1097/00006534-197802000-00015. [DOI] [PubMed] [Google Scholar]
  6. Freedman V. H., Shin S. I. Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium. Cell. 1974 Dec;3(4):355–359. doi: 10.1016/0092-8674(74)90050-6. [DOI] [PubMed] [Google Scholar]
  7. GROSSI C. E., AGOSTINO D., CLIFFTON E. E. The effect of human fibrinolysin on pulmonary metastases of Walker 256 carcinosarcoma. Cancer Res. 1960 Jun;20:605–608. [PubMed] [Google Scholar]
  8. Holland P. D., Browne O., Thornes R. D. The enhancing influence of proteolysis on E rosette forming lymphocytes (T cells) in vivo and in vitro. Br J Cancer. 1975 Feb;31(2):164–169. doi: 10.1038/bjc.1975.21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hoover H. C., Jr, Ketcham A. S. Techniques for inhibiting tumor metastases. Cancer. 1975 Jan;35(1):5–14. doi: 10.1002/1097-0142(197501)35:1<5::aid-cncr2820350103>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  10. Jones P. A., Laug W. E., Benedict W. F. Fibrinolytic activity in a human fibrosarcoma cell line and evidence for the induction of plasminogen activator secretion during tumor formation. Cell. 1975 Oct;6(2):245–252. doi: 10.1016/0092-8674(75)90015-x. [DOI] [PubMed] [Google Scholar]
  11. Jones P. A., Rhim J. S., Isaacs H., Jr, McAllister R. M. The relationship between tumorigenicity, growth in agar and fibrinolytic activity in a line of human osteosarcoma cells. Int J Cancer. 1975 Oct 15;16(4):616–621. doi: 10.1002/ijc.2910160411. [DOI] [PubMed] [Google Scholar]
  12. Laki K., Tyler H. M., Yancey S. T. Clot forming and clot stabilizing enzymes from the mouse tumor YPC-1. Biochem Biophys Res Commun. 1966 Sep 8;24(5):776–781. doi: 10.1016/0006-291x(66)90393-7. [DOI] [PubMed] [Google Scholar]
  13. Mak T. W., Rutledge G., Sutherland D. J. Androgen-dependent fibrinolytic activity in a murine mammary carcinoma (Shionogi SC-115 cells) in vitro. Cell. 1976 Feb;7(2):223–226. doi: 10.1016/0092-8674(76)90021-0. [DOI] [PubMed] [Google Scholar]
  14. Nagy B., Ban J., Brdar B. Fibrinolysis associated with human neoplasia: production of plasminogen activator by human tumours. Int J Cancer. 1977 May 15;19(5):614–620. doi: 10.1002/ijc.2910190504. [DOI] [PubMed] [Google Scholar]
  15. Newstead G. L., Griffiths J. D., Salsbury A. J. Fibrinolytic activity of carcinoma of the colorectum. Surg Gynecol Obstet. 1976 Jul;143(1):61–64. [PubMed] [Google Scholar]
  16. Peterson H. I., Kjartansson I., Korsan-Bengtsen K., Rudenstam C. M., Zettergren L. Fibrinolysis in human malignant tumours. Acta Chir Scand. 1973;139(3):219–223. [PubMed] [Google Scholar]
  17. Thornes R. D. Adjuvant therapy of cancer via the cellular immune mechanism or fibrin by induced fibrinolysis and oral anticoagulants. Cancer. 1975 Jan;35(1):91–97. doi: 10.1002/1097-0142(197501)35:1<91::aid-cncr2820350114>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  18. Thornes R. D., Deasy P. F., Carroll R., Reen D. J., MacDonnel J. D. The use of the proteolytic enzyme brinase to produce autocytotoxicity in patients with acute leukemia and its possible role in immunotherapy. Cancer Res. 1972 Feb;32(2):280–284. [PubMed] [Google Scholar]
  19. WOOD S., Jr Pathogenesis of metastasis formation observed in vivo in the rabbit ear chamber. AMA Arch Pathol. 1958 Oct;66(4):550–568. [PubMed] [Google Scholar]
  20. WOODS J. R. EXPERIMENTAL STUDIES OF THE INTRAVASCULAR DISSEMINATION OF ASCITIC V2 CARCINOMA CELLS IN THE RABBIT, WITH SPECIAL REFERENCE TO FIBRINOGEN AND FIBRINOLYTIC AGENTS. Bull Schweiz Akad Med Wiss. 1964 May;20:92–121. [PubMed] [Google Scholar]
  21. ZEIDMAN I. The fate of circulating tumors cells. I. Passage of cells through capillaries. Cancer Res. 1961 Jan;21:38–39. [PubMed] [Google Scholar]

Articles from Annals of Surgery are provided here courtesy of Lippincott, Williams, and Wilkins

RESOURCES